Table 1 Patient characteristics.

From: CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC)

Characteristics

No. (%) of patients

No. (%) of patients

No. (%) of patients

p

Group

All

CEA kin. ≤0.05

CEA kin. >0.05

 

Frequency

N = 192

N = 133

N = 25

 

Median age (range), years

68 (27–87)

67 (37–87)

70 (27–86)

0.87

Sex (n = 192)

   

0.74

   Male

108 (56.2)

74 (55.6)

13 (52)

 

   Female

84 (43.8)

59 (44.4)

12 (48)

 

ECOG PS (n = 179)

   

0.36

   0

88 (49.2)

67 (53.6)

9 (42.9)

 

  ≥1

91 (50.8)

58 (46.4)

12 (57.1)

 

Tumour location (n = 191)

   

0.39

   Right colon

60 (31.4)

35 (26.5)

7 (28)

 

   Left colon

89 (46.6)

65 (49.2)

15 (60)

 

   Rectum

42 (22.0)

32 (24.2)

3 (12)

 

Primary tumour in place (n = 192)

   

0.92

   No

106 (55.2)

76 (57.1)

14 (56)

 

   Yes

86 (44.8)

57 (42.9)

11 (44)

 

Synchronous metastasis (n = 192)

   

0.79

   No

59 (30.7)

39 (29.3)

8 (32)

 

   Yes

133 (69.3)

94 (70.7)

17 (68)

 

Metastatic sites

   

NA

   Liver

156 (48.3)

109 (46.2)

22 (57.9)

 

   Lung

86 (26.6)

68 (28.8)

10 (26.3)

 

   Nodes

46 (14.2)

33 (14)

4 (10.5)

 

   Peritoneal

18 (5.6)

10 (4.2)

2 (5.3)

 

   Others

17 (5.3)

16 (6.8)

0 (0)

 

No. of metastatic sites (n = 192)

   

0.69

   1

91 (47.4)

58 (43.6)

12 (48)

 

   ≥2

101 (52.6)

75 (56.4)

13 (52)

 

Line of chemotherapy (n = 192)

   

0.37

   First line

134 (69.8)

89 (66.9)

19 (76)

 

   ≥Second line

58 (30.2)

44 (33.1)

6 (24)

 
  1. NA not applicable, PS performance status.